# The efficacy of curcumin/Qing Dai combination in children with active ulcerative colitis: a multicenter retrospective cohort study.

- **DOI:** [10.3389/fped.2024.1342656](https://doi.org/10.3389/fped.2024.1342656)
- **Rating:** Limited (2.7 out of 5)
- **Verdict:** A first multicenter pediatric cohort offering hypothesis-generating evidence for CurQD in active ulcerative colitis, constrained by an uncontrolled design that cannot separate the herbal effect from concomitant therapy.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-14
- **Evaluation page:** https://www.nabu.science/paper/10.3389%2Ffped.2024.1342656

## Strengths

- **First multicenter pediatric CurQD cohort** The study addresses a genuine evidence gap by reporting curcumin/Qing Dai combination therapy in children with active UC/IBD-U across four centers, extending adult trial evidence into an understudied pediatric add-on setting.
  - Dimension: contribution
  - Location: Introduction; Results, Patients and Management
- **Real-world clinical setting and follow-up** The multicenter design with both induction and prolonged maintenance follow-up reflects real-world clinical use, supporting relevance to pediatric gastroenterologists considering adjunctive options in refractory disease.
  - Dimension: application pathway
  - Location: Results, Efficacy of Maintenance; Discussion
- **Candid disclosure of study limitations** The discussion openly acknowledges the retrospective design, missing data, ascertainment bias from endoscopy performed mainly in non-responders, and possible under-detection of pulmonary hypertension because echocardiograms were not routine.
  - Dimension: positioning
  - Location: Discussion, limitations paragraphs

## Limitations

- **Uncontrolled confounding from concurrent therapy** Most patients were on concurrent 5-ASA (63%), biologics (30%), or corticosteroids (20%) at induction, with no control group and no adjustment or stratification, so observed improvement cannot be attributed specifically to CurQD.
  - Dimension: methodological rigour
  - Location: Results, Patients and Management; Methods
- **Substantial and selective missing outcome data** Paired fecal calprotectin was available for only 12-15 of 30 patients and post-induction PUCAI was missing for four, with missingness treated as non-available without sensitivity analysis and endoscopy performed predominantly in non-responders.
  - Dimension: methodological rigour
  - Location: Results, Efficacy of Induction; Methods, Statistical Analysis
- **Internal inconsistencies and absent disclosures** Concomitant-medication percentages and flare counts differ between abstract and full text, the statistical description conflates parametric and nonparametric summaries, and no conflict-of-interest statement accompanies a study of a named commercial product.
  - Dimension: reporting
  - Location: Abstract vs. Results; Methods, Statistical Analysis; Management Regimen

## Reliability checks

Caveats (3 of 4 checks).

- **Internal coherence:** Noted. Several reporting inconsistencies between abstract and full text affect interpretation of exact response estimates but do not reverse core findings. The combined primary outcome is reported as separate components, and the statistical methods description is imprecise.
- **Research conduct:** Noted. Ethics approval is declared with an identifier but unverifiable from the paper. No conflict of interest statement is present despite a named commercial manufacturer of the study product, and data availability is restricted to request without a repository.
- **Reference integrity:** Pending

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
